SCHEDULE 13D/A 0001812275 XXXXXXXX LIVE 1 Common Stock 04/23/2025 false 0001633932 29668H708 ESSA PHARMA, INC.

Suite 720, 999 West Broadway Vancouver British Columbia A1 V5Z 1K5

Soleus Capital Master Fund L.P (475) 208-3178 104 Field Point Road, 2nd Floor Attn: Steven J. Musumeci Greenwich CT 06830 0001812275 N SOLEUS CAPITAL MASTER FUND, L.P. a WC N E9 0.00 2262026.00 0.00 2262026.00 2262026.00 N 5.1 PN Y SOLEUS CAPITAL, LLC a AF N DE 0.00 2262026.00 0.00 2262026.00 2262026.00 N 5.1 OO Y SOLEUS CAPITAL GROUP, LLC a AF N DE 0.00 2262026.00 0.00 2262026.00 2262026.00 N 5.1 OO Y SOLEUS CAPITAL MANAGEMENT, L.P. a AF N DE 0.00 2262026.00 0.00 2262026.00 2262026.00 N 5.1 PN Y SOLEUS GP, LLC a AF N DE 0.00 2262026.00 0.00 2262026.00 2262026.00 N 5.1 OO Y GUY LEVY a AF N X1 0.00 2262026.00 0.00 2262026.00 2262026.00 N 5.1 IN Common Stock ESSA PHARMA, INC. Suite 720, 999 West Broadway Vancouver British Columbia A1 V5Z 1K5 This Amendment No. 1 to Schedule 13D (this "Amendment") is being filed by Soleus Capital Master Fund, L.P. ("Master Fund"), Soleus Capital, LLC ("Soleus Capital"), Soleus Capital Group, LLC ("SCG"), Soleus Capital Management, L.P. ("SCM"), Soleus GP, LLC ("Soleus GP"), and Mr. Guy Levy (each of the foregoing, individually, a "Reporting Person", and collectively, the "Reporting Persons") with respect to the beneficial ownership of the Reporting Persons in Essa Pharma, Inc., a corporation existing under the laws of the Province of British Columbia, Canada (the "Issuer"). This Amendment is being filed to supplement and update the information set forth in the Schedule 13D as previously filed on April 15, 2025 (the "Schedule 13D"). Each Item included in this Amendment amends and restates the information disclosed in the corresponding Item of the Schedule 13D. Unless otherwise indicated herein, capitalized terms used but not defined in this Amendment shall have the same meanings herein as are ascribed to such terms in the Schedule 13D. Master Fund has entered into cash settled swap transactions with respect to which it receives payments calculated by reference to the rate of return on Common Stock in exchange for payments by Master Fund to the swap counterparty equal to a fixed or floating interest rate on the notional amount of the swap. As of the date of this Amendment, these swaps reflect economic exposure to an aggregate of 4,025,351 shares of Common Stock. Master Fund does not obtain any beneficial ownership of the Common Stock (including the power to vote or direct the voting, or dispose or direct the disposition, of the shares of Common Stock that are subject to the swaps) or any right to obtain the Common Stock in connection with these swap transactions, and may enter into additional swap transactions or terminate existing swap transactions at any time. As a result, the Reporting Persons disclaim beneficial ownership of the shares of Common Stock that are subject to the swaps transactions. Other than the Joint Filing Agreement attached as Exhibit 1 to the original Schedule 13D, or as otherwise described herein, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Persons and between such persons and any person with respect to any securities of the Issuer. 1. Joint Filing Agreement, dated April 15, 2025, among the Reporting Persons. (#) 2. Letter dated April 15, 2025 from Soleus Capital Management, L.P. to the Board of Directors of the Issuer. (#) # Previously filed as an exhibit to the original Schedule 13D filed by the Reporting Persons on April 15, 2025. SOLEUS CAPITAL MASTER FUND, L.P. /s/ Guy Levy 04/24/2025 /s/ Guy Levy 04/24/2025 /s/ Guy Levy 04/24/2025 SOLEUS CAPITAL, LLC /s/ Guy Levy 04/24/2025 /s/ Guy Levy 04/24/2025 SOLEUS CAPITAL GROUP, LLC /s/ Guy Levy 04/24/2025 SOLEUS CAPITAL MANAGEMENT, L.P. /s/ Guy Levy 04/24/2025 /s/ Guy Levy 04/24/2025 SOLEUS GP, LLC /s/ Guy Levy 04/24/2025 GUY LEVY /s/ Guy Levy 04/24/2025